Please assess the completion status of the following clinical trial:

Trial Title: Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Babies admitted to NICU or seen in follow clinic that have a diagnosis of hemangioma that is verified by Principal Investigator (PI) or Co-Principal Investigators.~Exclusion Criteria:~* Babies with PHACES (Posterior fossa, Hemangioma, Arterial lesions, Cardiac abnormalities, Eye abnormalities) syndrome~* Babies with cardiac conditions that may predispose to heart block~* Babies with persistent hypoglycemia~* Babies on medications that may interact with beta blockers~* Babies who are hemodynamically unstable and are requiring pressors to maintain blood pressure~* Babies who are on systemic corticosteroid therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Timolol (Type: EXPERIMENTAL): Application of 1-2 drops of Timolol maleate 0.5% ophthalmic aqueous solution to hemangioma twice daily.
- Placebo (Type: PLACEBO_COMPARATOR): Application of 1-2 drops of placebo gel twice daily to hemangioma.

Based on this trial design, predict the completion outcome and termination type (if applicable).